收稿日期: 2024-04-22
网络出版日期: 2024-11-25
基金资助
国家自然科学基金资助项目(82060565)
In vitro study of 5⁃FU combined with rhCYGB in treating hypoxia⁃induced chemotherapy resistance of hepatocellular carcinoma
Received date: 2024-04-22
Online published: 2024-11-25
目的 探讨联合使用重组人细胞珠蛋白（rhCYGB）靶向缺氧诱导的5-氟尿嘧啶（5-FU）治疗耐受在肝癌中的作用及机制。以期为改善难治性肝癌提供一种新的联合治疗策略。 方法 在常氧和缺氧条件下检测不同药物对肝癌细胞的半数抑制率并绘制量效曲线，评估不同氧浓度下肝癌细胞对5-FU的敏感性。使用CompuSyn和SynergyFinder 3.0软件分析不同浓度rhCYGB和5-FU在常氧和缺氧条件下处理肝癌细胞的联合效应。肿瘤干细胞成球实验评估联合用药对肝癌干细胞性的作用。流式细胞术检测联合用药对CD133阳性细胞亚群比例的影响。划痕实验评估联合用药对肝癌细胞迁移的影响。 结果 缺氧条件下5-FU处理Hep3B、Huh7和HepG2细胞IC50值显著高于常氧条件下IC50值（P < 0.05），分别为常氧条件下的15.27、4.25、2.34倍。常氧和缺氧条件下5-FU联合rhCYGB具有协同效应。与5-FU单药组相比，5-FU联合rhCYGB对肝癌干细胞球的形成具有抑制作用（P < 0.05），且可显著下调Hep3B细胞中CD133阳性亚群比例（P < 0.05）。常氧条件下rhCYGB联合5-FU处理48 h后对Hep3B细胞的迁移具有联合抑制作用（P < 0.05）。 结论 rhCYGB与5-FU联合运用在肝癌中具有协同效应；联合机制可能涉及干细胞性及细胞迁移能力的调控。
王毅 , 何硕 , 杨斯昀 , 章俊 . 5-氟尿嘧啶联合重组人细胞珠蛋白治疗缺氧诱导化疗耐受肝细胞癌的体外实验[J]. 实用医学杂志, 2024 , 40(22) : 3146 -3154 . DOI: 10.3969/j.issn.1006-5725.2024.22.005
Objective This study explores the efficacy and underlying mechanisms of combining rhCYGB with 5-FU to target hypoxia-induced treatment resistance in liver cancer. The aim is to develop a novel combinatorial therapy strategy for improving outcomes in patients with refractory liver cancer. Methods The half-maximal inhibitory concentration （IC50） of drugs on liver cancer cells under normoxia and hypoxia was determined， and dose-response curves were generated to assess sensitivity to 5-FU. The combined effects of rhCYGB and 5-FU were analyzed withCompuSyn and SynergyFinder 3.0. Tumor stem cell sphere formation assays and flow cytometry for CD133-positive cells were conducted to evaluate the impact on cancer stemness. Wound healing assays assessed the effects on migration. Results The IC50 values under hypoxia exhibited a significant fold change compared to normoxia（P < 0.05）， specifically a 15.27-fold， 4.25-fold， and 2.34-fold increase for Hep3B， Huh7， and HepG2 cells respectively. Assessment of drug combination effects demonstrated a synergistic interaction between 5-FU and rhCYGB. Compared to the 5-FU monotherapy group， the combination of 5-FU and rhCYGB exerted an inhibitory effect on the formation of liver cancer stem cell spheres （P < 0.05） and significantly downregulated the proportion of CD133-positive subpopulations in Hep3B cells （P < 0.05）. Wound healing assay results revealed a synergistic inhibitory effect on the migration of Hep3B cells after 48 hours of treatment with rhCYGB combined with 5-FU undernormoxia （P < 0.05）. Conclusions The combination of rhCYGB and 5-FU demonstrates synergistic effects in liver cancer. The underlying mechanism may involve the modulation of stemness and cell migration capacity.
Key words： rhCYGB; hypoxia; combination strategy; cancer stem cell; hepatocellular carcinoma
| 1 | SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries ［J］. CA Cancer J Clin， 2021， 71（3）： 209-249. doi:10.3322/caac.21660 |
| 2 | 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南（2022年版） ［J］. 中国实用外科杂志， 2022， 42（3）： 241-273. |
| 3 | 费发珠， 芦佳骏， 张帅， 等. 肝细胞癌免疫及靶向治疗在特殊人群中的临床应用进展 ［J］. 实用医学杂志， 2024， 40（6）： 738-742. |
| 4 | CHEN Z， HAN F， DU Y， et al. Hypoxic microenvironment in cancer： Molecular mechanisms and therapeutic interventions ［J］. Signal Transduct Target Ther， 2023， 8（1）： 70. doi:10.1038/s41392-023-01332-8 |
| 5 | STADLBAUER A， KINFE T M， EYüPOGLU I， et al. Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in Humans ［J］. Clin Cancer Res， 2021， 27（6）： 1641-1649. doi:10.1158/1078-0432.ccr-20-3580 |
| 6 | LI J Q， WU X， GAN L， et al. Hypoxia induces universal but differential drug resistance and impairs anticancer mechanisms of 5-fluorouracil in hepatoma cells ［J］. Acta Pharmacol Sin， 2017， 38（12）： 1642-1654. doi:10.1038/aps.2017.79 |
| 7 | IBRAHIM A M， NADY S， SHAFAA M W， et al. Radiation and chemotherapy variable response induced by tumor cell hypoxia： Impact of radiation dose， anticancer drug， and type of cancer ［J］. Radiat Environ Biophys， 2022， 61（2）： 263-277. doi:10.1007/s00411-022-00974-6 |
| 8 | JIN H， WANG L， BERNARDS R. Rational combinations of targeted cancer therapies： Background， advances and challenges ［J］. Nat Rev Drug Discov， 2023， 22（3）： 213-234. doi:10.1038/s41573-022-00615-z |
| 9 | 徐军红， 姚红兵， 王雪尧， 等. FOLFOX-肝动脉灌注化疗联合应用仑伐替尼和程序性死亡受体1抑制剂治疗中晚期肝癌 ［J］. 实用医学杂志， 2024， 40（6）： 762-767. |
| 10 | KIM H G， KIM C W， LEE D H， et al. Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer ［J］. Int J Mol Sci， 2019， 20（18）： 4366. doi:10.3390/ijms20184366 |
| 11 | CHEN F， ZHUANG M， ZHONG C， et al. Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway ［J］. Oncol Rep， 2015， 33（1）： 457-463. doi:10.3892/or.2014.3550 |
| 12 | THUY L T T， HAI H， KAWADA N. Role of cytoglobin， a novel radical scavenger， in stellate cell activation and hepatic fibrosis ［J］. Clin Mol Hepatol， 2020， 26（3）： 280-293. doi:10.3350/cmh.2020.0037 |
| 13 | CHAKRABORTY S， JOHN R， NAG A. Cytoglobin in tumor hypoxia： Novel insights into cancer suppression ［J］. Tumour Biol， 2014， 35（7）： 6207-6219. doi:10.1007/s13277-014-1992-z |
| 14 | HOANG D V， THUY L T T， HAI H， et al. Cytoglobin attenuates pancreatic cancer growth via scavenging reactive oxygen species ［J］. Oncogenesis， 2022， 11（1）： 23. doi:10.1038/s41389-022-00389-4 |
| 15 | ZHANG J， PEI Y， YANG W， et al. Cytoglobin ameliorates the stemness of hepatocellular carcinoma via coupling oxidative‐nitrosative stress signals ［J］. Mol Carcinog， 2018， 58（3）： 334-343. doi:10.1002/mc.22931 |
| 16 | IANEVSKI A， GIRI A K， AITTOKALLIO T. SynergyFinder 3.0： an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples ［J］. Nucleic Acids Res， 2022， 50（W1）： W739-W743. doi:10.1093/nar/gkac382 |
| 17 | BAO M H R， WONG C C L. Hypoxia， Metabolic Reprogramming， and Drug Resistance in Liver Cancer ［J］. Cells， 2021， 10（7）： 1715. doi:10.3390/cells10071715 |
| 18 | MALIER M， GHARZEDDINE K， LAVERRIERE M H， et al. Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer ［J］. Cancer Res， 2021， 81（23）： 5963-5976. doi:10.1158/0008-5472.can-21-1572 |
| 19 | XU G， LI M， WU J， et al. Circular RNA circNRIP1 Sponges microRNA-138-5p to Maintain Hypoxia-Induced Resistance to 5-Fluorouracil Through HIF-1α-Dependent Glucose Metabolism in Gastric Carcinoma ［J］. Cancer Manag Res， 2020， 12： 2789-2802. doi:10.2147/cmar.s246272 |
| 20 | XUAN Y， HUR H， HAM I H， et al. Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism ［J］. Exp Cell Res， 2014， 321（2）：219-230. doi:10.1016/j.yexcr.2013.12.009 |
| 21 | THUY LE T T， MORITA T， YOSHIDA K， et al. Promotion of Liver and Lung Tumorigenesis in DEN-Treated Cytoglobin-Deficient Mice ［J］. Am J Pathol， 2011， 179（2）： 1050-1060. doi:10.1016/j.ajpath.2011.05.006 |
| 22 | AJMEERA D， AJUMEERA R. Drug repurposing： A novel strategy to target cancer stem cells and therapeutic resistance ［J］. Genes Dis， 2024， 11（1）： 148-175. doi:10.1016/j.gendis.2022.12.013 |
| 23 | LIU Q， GUO Z， LI G， et al. Cancer stem cells and their niche in cancer progression and therapy ［J］. Cancer Cell Int， 2023， 23（1）： 305. doi:10.1186/s12935-023-03130-2 |
| 24 | MU?OZ-GALVáN S， VERDUGO-SIVIANES E M， SANTOS-PEREIRA J M， et al. Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors ［J］. J Exp Clin Cancer Res， 2024， 43（1）： 57. doi:10.1186/s13046-024-02988-y |
| 25 | OUYANG L， SUN M M， ZHOU P S， et al. LncRNA FOXD1-AS1 regulates pancreatic cancer stem cell properties and 5-FU resistance by regulating the miR-570-3p/SPP1 axis as a ceRNA ［J］. Cancer Cell Int， 2024， 24（1）： 4. doi:10.1186/s12935-023-03181-5 |
/
| 〈 |
|
〉 |